Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for allergic and immunological diseases, aiming to develop first-choice therapies that improve patient health and outcomes ¹. The company's core business model revolves around the clinical development of two primary product candidates: navenibart and STAR-0310. Astria Therapeutics generates revenue through the potential commercialization of these product candidates, which are currently in various stages of clinical development, and has not yet generated any revenue from product sales ². The primary customer segments for Astria Therapeutics would be patients suffering from hereditary angioedema (HAE) and atopic dermatitis (AD), as well as the healthcare providers who prescribe treatments for these conditions.

Navenibart, formerly known as STAR-0215, is Astria Therapeutics' lead product candidate. It is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating, and potentially life-threatening disease ³. The company believes navenibart has the potential to be a market-leading and patient-friendly chronic treatment option for HAE, aiming for administration every three and six months ⁴. Navenibart has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Commission for HAE treatment ⁵. The company initiated a Phase 3 trial of navenibart, called ALPHA-ORBIT, in February 2025 ⁶. This global, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of navenibart over a 6-month treatment period in up to 135 adults and 10 adolescents (open-label) with Type 1 or Type 2 HAE ⁷. Adult patients will be randomized to receive one of three navenibart dose arms: an initial 600 mg dose followed by 300 mg every 3 months (Q3M), 600 mg every six months (Q6M), or 600 mg Q3M, or placebo; adolescents will receive an initial 600 mg dose followed by 300 mg Q3M ⁸. The primary endpoint is time-normalized monthly HAE attacks at 6 months, with a key secondary endpoint being the proportion of participants who are attack-free at 6 months ⁹. After 6 months, patients may enter ORBIT-EXPANSE, a long-term open-label trial with flexible dosing ¹⁰. Top-line results from the ALPHA-ORBIT trial are anticipated in early 2027 ¹¹. In addition, Astria Therapeutics is developing autoinjector and pre-filled syringe drug device combinations to ease navenibart administration ¹².

STAR-0310 is the company's second product candidate, a monoclonal antibody OX40 antagonist incorporating YTE half-life extension technology, in clinical development for the treatment of atopic dermatitis (AD) ¹³. The goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD ¹⁴. The company initiated a Phase 1a trial of STAR-0310 in healthy subjects in January 2025 ¹⁵. This randomized, double-blind, placebo-controlled single ascending dose trial will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STAR-0310 in approximately 40 healthy adult participants ¹⁶. Early proof-of-concept results from this trial are anticipated in the third quarter of 2025 ¹⁷. Preclinical results for STAR-0310, shared in May 2024, showed a long mean half-life of 26 days in cynomolgus monkeys compared to 10-14 days for a typical non-half-life-extended IgG antibody, and an approximately 8-fold increase in binding affinity to human OX40 compared to telazorlimab ¹⁸. STAR-0310 also demonstrated significantly less antibody-dependent cellular cytotoxicity (ADCC) potential compared to rocatinlimab, with comparable potency ¹⁹.

For the fiscal year ended December 31, 2024, Astria Therapeutics reported losses from operations of $111.6 million ²⁰. This compares to losses from operations of $83.0 million for the year ended December 31, 2023 ²¹. As of December 31, 2024, the company had an accumulated deficit of $674.8 million ²². The filing does not provide specific figures for total revenue, gross profit, gross margin percentage, operating margin, net income, basic and diluted EPS, free cash flow, cash and equivalents, total debt, or net debt for the reported fiscal period.

Comparing year-over-year, the losses from operations increased from $83.0 million in 2023 to $111.6 million in 2024 ²³. The filing does not provide specific year-over-year comparisons for revenue growth by segment, margin expansion or contraction, or notable shifts in business mix.

Significant operational developments during the period include the initiation of the Phase 3 ALPHA-ORBIT trial for navenibart in February 2025 ²⁴, with top-line results anticipated in early 2027 ²⁵. The company also reported final results from the ALPHA-STAR target enrollment in December 2024, which showed a 91% reduction in monthly attack rate for a single 450 mg dose over 6 months, a 96% reduction in moderate and severe attacks, and a 94% reduction in acute rescue medication use, with 50% of patients being attack-free through 3 months and 25% through 6 months ²⁶. For Cohort 2, a 600 mg dose followed by a 300 mg dose three months later resulted in a 95% reduction in monthly attack rate, a 95% reduction in moderate and severe attacks, a 94% reduction in acute rescue medication use, and 67% of patients being attack-free over 6 months ²⁷. Cohort 3, receiving a 600 mg dose followed by a 600 mg dose one month later, showed a 92% reduction in monthly attack rate, a 96% reduction in moderate and severe attacks, a 91% reduction in acute rescue medication use, and 67% of patients being attack-free over 6 months ²⁸. Navenibart was generally well-tolerated with no serious treatment-emergent adverse events and no discontinuations ²⁹. Enrollment in ALPHA-STAR was expanded to a total of 29 patients ³⁰, all of whom have entered ALPHA-SOLAR, a long-term open-label trial assessing long-term safety and efficacy, with initial safety and efficacy data expected in mid-2025 ³¹. For STAR-0310, the company received IND clearance from the FDA in December 2024 ³² and initiated a Phase 1a clinical trial in healthy subjects in January 2025 ³³, with early proof-of-concept results expected in the third quarter of 2025 ³⁴.

Astria Therapeutics expects its existing cash, cash equivalents, and short-term investments to fund its operating expenses and capital expenditure requirements into mid-2027 ³⁵. This operating plan includes the development of navenibart, specifically supporting all program activities through the completion of the ALPHA-ORBIT Phase 3 trial, including activities related to the planned ORBIT-EXPANSE long-term trial and Phase 3 development and testing of drug device combinations for potential dosing of navenibart ³⁶. For STAR-0310, the plan covers the completion of the ongoing Phase 1a clinical trial in healthy subjects and any related anticipated milestone payments ³⁷.

A major growth area for Astria Therapeutics is the development of navenibart for hereditary angioedema (HAE). The company's vision for navenibart is to lead the HAE market and become the first-choice preventative treatment with administration every three and six months, aiming to normalize the lives of people living with HAE ³⁸. The global HAE market was estimated at $2.8 billion in 2023 and has the potential to grow to $5.4 billion by 2030, driven by earlier diagnoses, increased preventative treatment adoption, and expansion into more geographic regions ³⁹. The ALPHA-ORBIT Phase 3 trial, initiated in February 2025, is designed to support global registration, with top-line results anticipated in early 2027 ⁴⁰. The company is also developing autoinjector and pre-filled syringe drug device combinations to ease administration, which are planned for testing in the ORBIT-EXPANSE long-term trial to support commercialization approval ⁴¹.

Another significant growth vector is the development of STAR-0310 for atopic dermatitis (AD). The company's goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD ⁴². The moderate-to-severe AD treatment market was approximately $7 billion in 2022 and has the potential to grow to $26 billion by 2030, attributed to increased drug-treatment rates, new therapies, and dermatologists' growing comfort with biologics ⁴³. STAR-0310 incorporates YTE half-life extension technology to enable infrequent dosing, addressing the need for a safe, effective, and infrequently administered AD treatment ⁴⁴. The Phase 1a clinical trial in healthy subjects, initiated in January 2025, is expected to yield early proof-of-concept results in the third quarter of 2025 ⁴⁵. Assuming positive Phase 1a results, a proof-of-concept clinical trial in AD patients is planned to demonstrate initial efficacy, safety, tolerability differentiation, and reduced treatment burden due to extended half-life ⁴⁶. The company also sees an opportunity to explore STAR-0310 in additional allergic and immunological indications ⁴⁷.

The company expects its expenses to increase substantially due to ongoing clinical trials, preclinical and nonclinical studies, manufacturing clinical supplies for navenibart's Phase 3 program, ramping up efforts for commercial supply manufacturing, and developing drug device combinations ⁴⁸. The company anticipates incurring significant expenses and operating losses for the foreseeable future ⁴⁹.

Astria Therapeutics' planned capital allocation includes funding activities for navenibart through the completion of the ALPHA-ORBIT Phase 3 trial and other navenibart activities beyond mid-2027, including the planned ORBIT-EXPANSE long-term trial, drug-device combination development, launch, and commercialization activities if marketing approval is obtained ⁵⁰. For STAR-0310, capital is allocated for activities beyond the ongoing Phase 1a trial and for any development outside of AD ⁵¹. The company will need to raise additional capital to fund activities for navenibart beyond mid-2027 and for STAR-0310 activities beyond the ongoing Phase 1a trial ⁵².

Management has explicitly flagged several structural headwinds and execution risks to the growth plan. The business is entirely dependent on the success of navenibart and STAR-0310, and there is no assurance that sufficient preclinical, clinical, or other data will be generated to receive regulatory approval ⁵³. Interim and preliminary clinical trial data may change as more data become available and are subject to audit and verification, which could result in material changes in final data ⁵⁴. Clinical trials are costly, time-consuming, difficult to enroll, and inherently risky, with no guarantee of demonstrating safety and efficacy on expected timelines or to regulatory satisfaction ⁵⁵. Later-stage clinical trials for STAR-0310 are expected to be larger and more expensive due to AD not being a rare disease ⁵⁶. Navenibart, STAR-0310, or future product candidates may cause adverse events or undesirable side effects, or have unexpected properties that could delay or halt clinical trials, prevent regulatory approval, limit commercial viability, or result in negative consequences post-approval ⁵⁷. The company faces substantial competition from other pharmaceutical and biotechnology companies, which could negatively impact operating results ⁵⁸. Product development is a lengthy and expensive process with an uncertain outcome, and earlier results may not predict future clinical trial outcomes ⁵⁹. Reliance on in-licensed intellectual property for STAR-0310 and potential need for other licenses for both programs pose risks if obligations are not met or licenses are terminated ⁶⁰. The company relies on third parties for preclinical studies and clinical trials, and their unsatisfactory performance could significantly harm the business ⁶¹. Maintaining master cell banks and building sufficient manufacturing capacity through third-party manufacturers for navenibart, STAR-0310, and any future biologic candidates is critical, and failure could materially harm the business and require earlier capital raises ⁶². Forecasts of cash usage and runway may not be accurate, potentially forcing delays, reductions, or elimination of product development or commercialization efforts ⁶³.

Astria Therapeutics faces material risks including its entire business dependence on the success of navenibart for hereditary angioedema (HAE) and STAR-0310 for atopic dermatitis (AD), with no assurance of generating sufficient data for regulatory approval ⁶⁴. Interim and preliminary clinical trial data are subject to change and audit, potentially leading to material differences in final data ⁶⁵. The company will need substantial additional funding, and an inability to raise capital on acceptable terms could force delays, reductions, or elimination of product development or commercialization efforts ⁶⁶. Raising additional capital may dilute stockholders, restrict operations, or require relinquishing rights to technologies or product candidates ⁶⁷. The company has never generated revenue from product sales and may never be profitable ⁶⁸. Marketing approval has never been obtained for a product candidate, and future approvals may be delayed or unobtainable ⁶⁹. Clinical trials are costly, time-consuming, difficult to enroll, and inherently risky, with later-stage STAR-0310 trials expected to be larger and more expensive due to AD not being a rare disease ⁷⁰. Navenibart, STAR-0310, or future product candidates may cause adverse events or undesirable side effects, delaying or preventing regulatory approval or limiting commercial viability ⁷¹. Substantial competition from other pharmaceutical and biotechnology companies could negatively impact operating results ⁷². Product development is lengthy and expensive with uncertain outcomes, and earlier results may not predict future clinical trial results ⁷³. Reliance on in-licensed intellectual property for STAR-0310 and potential need for other licenses for both programs poses risks if obligations are not met or licenses are terminated ⁷⁴. The company relies on third parties for preclinical studies and clinical trials, and their unsatisfactory performance could significantly harm the business ⁷⁵. Maintaining master cell banks and building sufficient manufacturing capacity through third-party manufacturers is critical, and failure could materially harm the business and require earlier capital raises ⁷⁶. Forecasts of cash usage and runway may not be accurate, potentially forcing delays, reductions, or elimination of product development or commercialization efforts ⁷⁷. The company has incurred significant losses since inception, has a limited operating history, and anticipates continued significant losses, potentially never achieving profitability ⁷⁸. Inability to obtain and maintain sufficient patent and/or regulatory protection, or if the scope is not broad enough, could allow competitors to commercialize similar products, adversely affecting commercialization success ⁷⁹. The price of common stock has been and is likely to continue to be highly volatile, potentially resulting in substantial losses for stockholders ⁸⁰. Geopolitical events, including civil or political unrest (such as the war between Russia and Ukraine and the conflict in the Middle East), terrorist activity, and unstable governments and legal systems, could disrupt operations, delay clinical trials, harm future revenue and financial condition, and increase costs and expenses ⁸¹. Changes in U.S./China trade policies, such as export controls, capital controls, or tariffs, may increase manufacturing costs, affect demand, or impact the competitive position of product candidates ⁸². The company holds cash and cash equivalents in deposit accounts at one financial institution that typically exceed the Federal Deposit Insurance Corporation standard deposit insurance limit of $250,000 ⁸³, posing a risk of loss or delayed access to uninsured funds if the institution fails ⁸⁴.

Management's message to shareholders emphasizes the company's focus on developing first-choice therapies for allergic and immunological diseases, with a vision for navenibart to lead the HAE market as the first-choice preventative treatment with administration every three or six months, aiming to normalize the lives of people living with HAE ⁸⁵. For STAR-0310, the goal is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD ⁸⁶. The company anticipates top-line results from the ALPHA-ORBIT trial in early 2027 ⁸⁷ and early proof-of-concept results from the Phase 1a trial of STAR-0310 in the third quarter of 2025 ⁸⁸. Management's strategic priorities include advancing navenibart through its Phase 3 program, including the ALPHA-ORBIT trial and the planned ORBIT-EXPANSE long-term trial, and developing drug-device combinations for ease of administration ⁸⁹. A second priority is the clinical development of STAR-0310, starting with the ongoing Phase 1a trial and planning a subsequent proof-of-concept trial in AD patients ⁹⁰. A third strategic priority involves expanding the pipeline, with an opportunity to explore STAR-0310 in additional allergic and immunological indications ⁹¹.